Navigation Links
Alzheimer's Drugs Also Treat Behavioral, Psych Problems
Date:12/17/2008

Therapy effective at same dosage used to improve cognitive impairment, study says

WEDNESDAY, Dec. 17 (HealthDay News) -- Drugs used to treat Alzheimer's patients' cognitive symptoms are also a safe and effective therapy for behavioral and psychological symptoms such as aggression, wandering and paranoia, according to U.S. researchers.

They reviewed nine studies that examined the effectiveness of three popular cholinesterase inhibitors in managing Alzheimer's patients' behavioral and psychological symptoms, and found the drugs were effective at the same dosage used to improve cognitive impairment.

The study was published in the December issue of Clinical Interventions in Aging.

About 90 percent of Alzheimer's patients have behavioral and psychological symptoms. Cholinesterase inhibitors boost levels of a brain chemical called acetylcholine, which assists memory, thought and judgment.

"There is a need for safe alternatives to the antipsychotic drugs currently used to manage the behavioral and psychological symptoms of Alzheimer's disease. The results of the studies we analyzed are encouraging and suggestive that cholinesterase inhibitors are safe and effective alternatives," review co-author Dr. Malaz Boustani, an assistant professor of medicine at the Indiana University School of Medicine, said in a university news release.

"However, [cholinesterase inhibitors] are underutilized and typically prescribed for less than three months and for less than 10 percent of patients with Alzheimer's disease. Our findings might provide clinicians with useful data to justify the appropriate use of these medications," said Boustani, a researcher at the IU Center for Aging Research and chief research officer of the Indianapolis Discovery Network for Dementia.

"This class of medications has already been approved the Food and Drug Administration to manage symptoms of Alzheimer's type dementia, although the potential benefits on behavioral symptoms are not frequently identified by many prescribers," study co-author Noll Campbell, a clinical pharmacy specialist in geriatric psychiatry with Wishard Health Services, said in the news release. The use of cholinesterase inhibitors could reduce "the use of more harmful medications that are needed to control [dementia-related] behaviors."

More information

The U.S. National Institute on Aging has more about Alzheimer's medications.



-- Robert Preidt



SOURCE: Indiana University, news release, Dec. 9, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Alzheimers Research Target May Be a Dead End
2. FDA Adds Suicide Warning to Epilepsy Drugs
3. UIC researchers hunting drugs for devastating parasitic disease
4. China Sky One Medical, Inc. Obtains Production Rights for Two Additional Drugs
5. Sanofi-aventis U.S. Announces Increased Access to Drugs for Low Income Patients Through Expanded PAP Programs
6. FDA Puts Black-Box Warning on Bowel-Cleansing Drugs
7. Cancer drugs in the pipeline
8. A new class of anti-inflammatory drugs
9. 2 Diabetes Drugs Double Fracture Risk in Women
10. Two common diabetes drugs double the risk of fractures in women
11. Popular class of diabetes drugs doubles risk of fractures in women
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Alzheimer's Drugs Also Treat Behavioral, Psych Problems
(Date:5/24/2017)... ... 2017 , ... The CFOs included on this list lead ... the nation and help their organizations navigate the challenges in healthcare today. These ... developing successful hospital and health system strategy. , Becker's Hospital Review has published ...
(Date:5/24/2017)... (PRWEB) , ... May 24, 2017 , ... Technique, technique, ... back injury when either lifting weights for strength training and exercise or simply lifting ... Center . , “Body position is everything,” Dr. Chang says. “Improper technique in lifting ...
(Date:5/23/2017)... ... May 23, 2017 , ... MDLand ... Integration company, announced today that its iClinic V12.2 solution has achieved approval from ... NCQA recently introduced PCMH 2017 standards which emphasize team-based care with a significant ...
(Date:5/23/2017)... ... ... Allegheny Health Network and the Alexis Joy D’Achille Foundation ... at West Penn Hospital , a unique facility that will offer the most ... Construction of the Center is underway with a scheduled opening in the fall of ...
(Date:5/23/2017)... ... May 23, 2017 , ... Cambridge, MA, May 23, 2017—Total ... according to a Workers Compensation Research Institute (WCRI) study, a contrast from the ... System: CompScope™ Benchmarks, 17th Edition looks at indemnity and medical payments for ...
Breaking Medicine News(10 mins):
(Date:5/9/2017)... , May 9, 2017  Oramed Pharmaceuticals Inc. ... a clinical-stage pharmaceutical company focused on the development ... the Canadian Intellectual Property Office has granted Oramed ... Administration of Exenatide". The patent covers Oramed,s invention ... GLP-1 is an incretin hormone that stimulates ...
(Date:5/6/2017)... Provista , a proven leader in the supply chain industry ... Jim Cunniff as the company,s new president and CEO. ... Provista, including most recently serving as the president and CEO ... He assumed his new role with Provista on May 1, ... says Jody Hatcher , president, Sourcing and Collaboration Services ...
(Date:5/4/2017)... MEMPHIS, Tenn. , May 4, 2017 /PRNewswire/ ... of Infection Control, Ultraviolet-C light as ... demonstrated Tru-D SmartUVC,s ability to reduce bioburden on ... influenced bioburden reduction on high-touch, complex medical equipment ... in surgical infections. "This study further ...
Breaking Medicine Technology: